https://www.businesswire.com/news/home/20200528005252/en/Largest-European-Quantitative-Study-Peanut-Allergy-Confirms
LONDON--(BUSINESS WIRE)--Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing and commercializing treatments for life-threatening food allergies, today announced that findings from APPEAL-1 (Allergy to Peanuts ImPacting Emotions A…
Create an account or login to join the discussion